

This volume is dedicated to the memory of

W.L. GERARD

I.B. WEINSTEIN

CANCER GENOMICS & PROTEOMICS

Published by the International Institute of Anticancer Research

ISSN (print): 1109-6535; ISSN (online): 1790-6245

Volume 6, 2009

INDEX

Editorial Board

- A. Seth** Editor-in-Chief
Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada
- J.G. Delinassios** Managing Editor and Executive Publisher,
International Institute of Anticancer Research, Athens, Greece
- L.A. Aaltonen** Department of Medical Genetics, University of Helsinki, Finland
- S. Aaronson** Derarld H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, NY, USA
- R. Abagyan** The Scripps Research Institute, La Jolla, CA, USA
- F. Ahmed** Department of Radiation Oncology, East Carolina University School of Medicine, Greenville, NC, USA
- J.D. Aitchison** Institute for Systems Biology, Seattle, WA, USA
- W. Ansorge** IAET, Borex, Switzerland
- S. Antonarakis** Division of Medical Genetics, University of Geneva Medical School, Switzerland
- F.G. Barr** Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
- A.M. Burger** Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
- A.M. Chinnaiyan** Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA
- B.F.C. Clark** Department of Molecular Biology, University of Aarhus, Denmark
- R. Clarke** Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA
- I. Dunham** The Wellcome Trust Sanger Centre, Wellcome Trust Genome Campus, Cambridge, UK
- T. Efferth** German Cancer Research Center, Pharmaceutical Biology, Heidelberg, Germany
- N.A. Ellis** Department of Medicine University of Chicago, IL, USA
- J.A. Fernandes-Pol** Metalloproteomics, LLC, Chesterfield, MO, USA
- C.V. Forst** McClintock Resource, Bioscience Division, Los Alamos National Laboratory, NM, USA
- M. Fountoulakis** F. Hoffman-La Roche Pharmaceutical Research, Basel, Switzerland
- W.L. Gerald** Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- J.W. Gray** Cancer Genetics Program, Comprehensive Cancer Center, University of California San Francisco, CA, USA
- B.B. Haab** Van Andel Research Institute, Grand Rapids, MI, USA
- C.-H. Heldin** Ludwig Institute for Cancer Research, Uppsala, Sweden
- J.D. Hoheisel** Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany
- R.P. Huang** Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, USA
- T.H.M. Huang** Comprehensive Cancer Center, Human Cancer Genetics Program, Ohio State University, Columbus, OH, USA
- Y. Ito** Institute of Molecular and Cell Biology, Oncology Research Institute, Yon Loo Lin School of Medicine, National University of Singapore, Singapore
- S.C. Jhanwar** Departments of Pathology and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- V.C. Jordan** Fox Chase Cancer Center, Philadelphia, PA, USA
- J. Ju** Translational Research Laboratories, State University of New York, School of Medicine, Stony Brook, NY, USA
- A. Kallioniemi** Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Finland
- O.P. Kallioniemi** Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland
- M. Kanehisa** Bioinformatics Center, Institute for Chemical Research, Kyoto University, Japan
- S.E. Kern** Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA
- K. Khalili** College of Science and Technology, Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA
- D.G. Kieback** DIAKO, Ev. Diakonie-Hospital, Bremen, Germany
- S.D. Kottaridis** Department of Virology, Hellenic Anticancer Institute, Athens, Greece
- B. Léylard-Jones** Winship Cancer Center, Emory University School of Medicine, Atlanta, GA, USA
- P. Lichter** Deutsches Krebsforschungszentrum, Heidelberg, Germany
- A. Lindblom** Karolinska Hospital, Department of Molecular Medicine and Surgery, Stockholm, Sweden
- G. Lubec** Department of Pediatrics, University of Vienna, Austria
- J. Lyons-Weiler** Department of Pathology, Center for Oncology Informatics, University of Pittsburgh, PA, USA
- P.J. McCormick** The Center for Functional Genomics, Gen*NY*Sis Center for Excellence in Cancer Genomics, University of Albany, SUNY, Rensselaer, NY, USA
- J.D. Minna** Hamon Center for Therapeutic Oncology, University of Texas, Southwestern Medical Center at Dallas, TX, USA
- F. Mitelman** Department of Clinical Genetics, University Hospital, Lund, Sweden
- P. Nelson** Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- C. Nicot** Department of Microbiology, Immunology and Molecular Genetics, University of Kansas Medical Center, Kansas City, KS, USA
- L. O'Driscoll** School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland

- R. Ohlsson** Department of Development and Genetics, Evolution Biology Center, Uppsala University, Sweden
I. Pastan Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, USA
C.D. Platsoucas College of Sciences, Old Dominion University, Norfolk, VA, USA
J. Quackenbush Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
G. Rechavi Pediatric Hemato-Oncology Department, Sheba Medical Center, Tel-Hashomer, Israel
R.H. Reeves Department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
K.L. Reichelt Institute of Pediatric Research, The National Hospital, University of Oslo, Norway
T. Ried Center for Cancer Research, Genetics Branch, NCI, NIH, Bethesda, MD, USA
G. Rimbach Institute for Human Nutrition and Food Science, Christian-Albrechts-University, Kiel, Germany
K.D. Rodland Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
C. Sansom The School of Crystallography, Birbeck College, University of London, UK
Y. Sakaki Human Genome Research Group, RIKEN Genomic Sciences Center, Yokohama, Japan
N.A. Saunders Centre for Immunology and Cancer Research, Princess Alexandra Hospital, University of Queensland, Australia
S.W. Scherer The Hospital for Sick Children, Department of Genetics, University of Toronto, ON, Canada
G.V. Sherbet University of Newcastle, Merz Court, Department of Electrical and Electronic Engineering, Newcastle-upon-Tyne, UK
J. Schneider Universidad Rey Juan Carlos, Facultad de Ciencias de la Salud, Alcorcón (Madrid), Spain
Y. Shimonishi Nagahama Institute of Bioscience and Technology, Shiga, Japan
K.K. Singh Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA
S. Smith City of Hope Cancer Center, Department of Cell and Tumor Biology, Duarte, CA, USA
D. Sudar Life Sciences Division, Lawrence Berkeley Laboratory, Berkeley, CA, USA
A.-C. Syvänen Department of Medical Sciences, Uppsala University Hospital, Sweden
K. Tanaka Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan
J.M. Trent Tgen, Phoenix, AZ, USA
G. Tsangaris Foundation of Biomedical Research of the Academy of Athens, Central Unit of Genomics-Proteomics, Athens, Greece
L.-C. Tsui The Hospital for Sick Children, University of Toronto, ON, Canada
A. Ullrich Department of Molecular Biology, Max-Planck Institute of Biochemistry, Martinsried, Germany
G.F. Vande Woude Laboratory of Molecular Oncology, Van Andel Institute, Grand Rapids, MI, USA
D.K. Watson Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
I.B. Weinstein Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, New York, NY, USA
K. Williams Keck Laboratory, Department of Molecular Biophysics and Biochemistry, New Haven, CT, USA
A.T. Yeung Fox Chase Cancer Center, Philadelphia, PA, USA
H. Zhang Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, MEDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Editorial Office:

International Institute of Anticancer Research
 1st km Kapandritiou-Kalamou Road,
 P.O. Box 22, Kapandriti, Attiki, 19014, Greece.
 Tel: +30 22950 52945, Fax: +30 22950 53389
 e-mail: journals@iiar-anticancer.org. Website: www.iiar-anticancer.org

Manuscripts, correspondence, requests for sample copies and orders should be addressed to: Dr. John G. Delinassios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: editor@iiar-anticancer.org

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, 2075 Bayview Avenue, Room S112a, Toronto, ON, Canada M4N 3M5. Fax: +1 416 480 5737, e-mail: genomics.proteomics@utoronto.ca

Acknowledgements

The following Organisations supported many of the works published in CANCER GENOMICS & PROTEOMICS, Volume 6, 2009.

American-Italian Cancer Foundation, New York, NY,
U.S.A.

Anders Otto Swärd/Ulrika Eklund Foundation, Sweden
Arizona Cancer Center Bioinformatics Core, Tucson, AZ,
U.S.A.

BioRag (Bioresource for array genes), www.biorag.org

Cancer Research Foundation in Northern Sweden
Cancer Research Wales, Cardiff, U.K.
Centro de Investigación Biomédica de Occidente, IMSS,
Guadalajara, Jalisco, Mexico
China Medical University and Hospital, Taichung, Taiwan,
R.O.C.
Chulabhorn Research Institute, Bangkok, Thailand
Compagnia di San Paolo, Turin, Italy

Genomics and Proteomics Shared Services, University of
Arizona, Tucson, AZ, U.S.A.
Graduate School of Chulalongkorn University, Bangkok,
Thailand

Han Cell, Inc., Republic of Korea
Higher Education Commission of Pakistan

Johannes Gutenberg University, Mainz, Germany

National Cancer Institute (NCI), NIH, Bethesda, MD,
U.S.A.
National Health and Medical Research Council, Australia
National Institutes of Health (NIH), Bethesda, MD, U.S.A.

National Natural Science Foundation, Arlington, VA,
U.S.A.

National Science Council, Taipei, Taiwan, R.O.C.
Nilsson-Ehle Foundation, Sweden
NY LILAC Foundation, U.S.A.
NYSTAR Centers for Advanced Sensor Technology,
Albany, NY, U.S.A.

Prevent Cancer Foundation, Alexandria, VA, U.S.A.
Progen Pharmaceuticals Inc., Redwood City, CA, U.S.A.
Progen Pharmaceuticals, Inc., Queensland, Australia

School of Medicine (SOM), Stony Brook University
Medical Center (SBU), Stony Brook, NY, U.S.A.
Stockholm Cancer Foundation, Sweden
Swedish Cancer Society
Swedish Research Council

Terry Fox Cancer Research Foundation, Taichung, Taiwan,
R.O.C.
The American Research Foundation, U.S.A.
The Fong Family Foundation, U.K.
Tissue Bank in China Medical University, Taichung,
Taiwan, R.O.C.

U.S. Public Health Service Commissioned Corps (USPHS),
Rockville, MD, U.S.A.

Wessex Cancer Trust, Southampton, U.K.
Wessex Medical Research, Southampton, U.K.

Contents, Volume 6, 2009

Number 1

Immune Response Signatures of Benzo(α)pyrene Exposure in Normal Human Mammary Epithelial Cells in the Absence or Presence of Chlorophyllin. K. JOHN, C. KESHAVA, D.L. RICHARDSON, A. WESTON, J. NATH (<i>Morgantown, WV; Bethesda, MD; Triangle Park, NC, USA</i>)	1
Relative Quantification of <i>Cytochrome P450 1B1</i> Gene Expression in Peripheral Leukocytes Using LightCycler. S. HELMIG, B. HADZAAD, J. DÖHREL, J. SCHNEIDER (<i>Giessen, Germany</i>)	13
Phenotypic Subpopulations of Metastatic Colon Cancer Stem Cells: Genomic Analysis. I.L. BOTCHKINA, R.A. ROWEHL, D.E. RIVADENEIRA, M.S. KARPEH JR, H. CRAWFORD, A. DUFOUR, J. JU, Y. WANG, Y. LEYFMAN, G.I. BOTCHKINA (<i>San Francisco, CA; Stony Brook; New York, NY, USA</i>)	19
Down-regulation of Microfilamental Network-associated Proteins in Leukocytes of Breast Cancer Patients: Potential Application to Predictive Diagnosis. M. BRAUN, M. FOUNTOULAKIS, A. PAPADOPOULOU, K. VOUGAS, I. SEIDEL, T. HÖLLER, K. YEGHIAZARYAN, H.H. SCHILD, W. KUHN, O. GOLUBNITSCHAJA (<i>Bonn, Germany; Athens, Greece</i>)	31
Label-free Global Serum Proteomic Profiling Reveals Novel Celecoxib-modulated Proteins in Familial Adenomatous Polyposis Patients. N. FATIMA, D. CHELIUS, B.T. LUKE, M.YI, T. ZHANG, S. STAUFFER, R. STEPHENS, P. LYNCH, K. MILLER, T. GUSZCZYNSKI, D. BORING, P. GREENWALD, I.U. ALI (<i>Bethesda, Frederick, MD; San Jose, CA; Houston, TX, USA</i>).	41
Abstracts of the 3rd International Conference of the Hellenic Proteomics Society, March 30 - April 1, 2009 . . .	51
Erratum	73

Number 2

Surface-enhanced Laser Desorption/Ionisation Time-of-flight Mass Spectrometry to Detect Breast Cancer Markers in Tears and Serum. A. LEBRECHT, D. BOEHM, M. SCHMIDT, H. KOELBL, F.H. GRUS (<i>Mainz, Germany</i>)	75
Effect of Dietary Genistein on Phase II and Antioxidant Enzymes in Rat Liver. H. WIEGAND, A.E. WAGNER, C. BOESCH-SAADATMANDI, H.-P. KRUSE, SABINE KULLING, G. RIMBACH (<i>Kiel; Nuthetal, Germany</i>)	85
A Gene Expression Profiling Approach Assessing Celecoxib in a Randomized Controlled Trial in Prostate Cancer. P. SOORIAKUMARAN, P. MACANAS-PIRARD, G. BUCCA, A. HENDERSON, S.E.M. LANGLEY, R.W. LAING, C.P. SMITH, E.E. LAING, H.M. COLEY (<i>Guildford, Surrey, UK</i>)	93
Reduced Expression of BMPR-IB Correlates with Poor Prognosis and Increased Proliferation of Breast Cancer Cells. S.M. BOKOBZA, L. YE, H.E. KYNASTON, R.E. MANSEL, W.G. JIANG (<i>Cardiff, UK</i>)	101
Differences in mRNA and microRNA Microarray Expression Profiles in Human Colon Adenocarcinoma HT-29 Cells Treated with either Intensity-modulated Radiation Therapy (IMRT), or Conventional Radiation Therapy (RT). F.E. AHMED, P.W. VOS, C. JEFFRIES, J.E. WILEY, D.A. WEIDNER, H. MOTA, C. BONNERUP, C. SIBATA, R.R. ALLISON (<i>Greenville; Chapel Hill, NC, USA</i>)	109
Errata	129

Number 3

MicroRNA-222 Regulates Cell Invasion by Targeting Matrix Metalloproteinase 1 (MMP1) and Manganese Superoxide Dismutase 2 (SOD2) in Tongue Squamous Cell Carcinoma Cell Lines. X. LIU, J. YU, L. JIANG, A. WANG, F. SH, H. YE, X. ZHOU (*Chicago, IL, USA; Guangzhou, China*) 131

Proteomic Analysis of Archival Breast Cancer Serum. B.A. ZEIDAN, R.I. CUTRESS, N. MURRAY, G.R. COULTON, C. HASTIE, G. PACKHAM, P.A. TOWNSEND (*Southampton; Gosport; London; Portsmouth, UK*) 141

Increased Levels of Macrophage-secreted Cathepsin S during Prostate Cancer Progression in TRAMP Mice and Patients. C. LINDAHL, M. SIMONSSON, A. BERGH, E. THYSELL, H. ANTTI, M. SUND, P. WIKSTRÖM (*Umeå, Sweden*) 149

Gene Expression Analysis of HCT116 Colon Tumor-derived Cells Treated with the Polyamine Analog PG-11047. N.A. IGNATENKO, H.F. YERUSHALMI, R. PANDEY, K.L. KACHEL, D.E. STRINGER, L.J. MARTON, E.W. GERNER (*Haifa, Israel; Tucson, AZ; Redwood City, CA, USA*) 161

Diagnosis of Breast Cancer by Tear Proteomic Pattern. A. LEBRECHT, D. BOEHM, M. SCHMIDT, H. KOELBL, R.L. SCHWIRZ, F.H. GRUS (*Mainz, Germany*) 177

Association of the 677C→T Polymorphism in the *MTHFR* Gene with Colorectal Cancer in Mexican Patients. M.P. GALLEGOS-ARREOLA, J.E. GARCÍA-ORTIZ, L.E. FIGUERA, A.M. PUEBLA-PÉREZ, G. MORGAN-VILLELA, G.M. ZÚÑIGA-GONZÁLEZ (*Jalisco, México*) 183

Gene Expression Profiling in Response to Estradiol and Genistein in Ovarian Cancer Cells. L.P. PARKER, D.D. TAYLOR, S. KESTERSON, C. GERCEL-TAYLOR (*Louisville, KY, USA*) 189

Number 4

* Review: Pathogenetic and Clinical Relevance of MicroRNAs in Colorectal Cancer. N. VALERI, C.M. CROCE, M. FABBRI (*Columbus, OH, USA; Ferrara, Meldola, Italy*) 195

Effect of Expressional Alteration of KAI1 on Breast Cancer Cell Growth, Adhesion, Migration and Invasion. F.A. MALIK, A.J. SANDERS, M.A. KAYANI, W.G. JIANG (*Cardiff, Wales, UK; Islamabad, Pakistan*) 205

Elucidation of the Transmission of a Novel Mutation in *BRCA1* (1125delCT) in a Family with Multiple Cases of Breast Cancer. E. RAZIS, I. BELOGIANNI, V. SIAMANTA, A. APESSOS, V. KYRIAKOPOULOU, E. PAPADOPOULOU, M. SARIYANNI, D. THEOFILOPOULOS, S. LABROPOULOS, G. NASIOULAS (*Athens, Greece*) 215

MGMT Promoter Hypermethylation in a Series of 104 Glioblastomas. M. MELLAI, V. CALDERA, L. ANNOVAZZI, A. CHIÒ, M. LANOTTE, P. CASSONI, G. FINOCCHIARO, D. SCHIFFER (*Vercelli; Turin; Milan, Italy*) 219

Comparative Proteomic Analysis of Lung Cancer Cell Line and Lung Fibroblast Cell Line. A. RUBPORN, C. SRISOMSAP, P. SUBHASITANONT, D. CHOKCHAICHAMNANKIT, K. CHIABLAEM, J. SVASTI, P. SANGVANICH (*Bangkok, Thailand*) 229

PGF Isoforms, PLGF-1 and PGF-2, in Colorectal Cancer and the Prognostic Significance. A. ESCUDERO-ESPARZA, T.A. MARTIN, M.L. DAVIES. W.G. JIANG (*Cardiff, UK*) 239

* Review (page 195)

Number 5

Chromosomal Alterations and Mutagen Sensitivity in Human Mucosal Cells of the Oropharynx and Lymphocytes Caused by BPDE. M. REITER, P. BAUMEISTER, S. ZIEGER, U. HARRÉUS (*Munich, Germany*) 247

Inhibition of mTOR Activates the MAPK Pathway in Glioblastoma Multiforme. L. ALBERT, M. KARSY, R. MURALI, M. JHANWAR-UNIYAL (*Valhalla, NY, USA*) 255

Resveratrol Induces Apoptosis in Human SK-HEP-1 Hepatic Cancer Cells. H.Y. CHOI, S.A. CHONG, M.J. NAM (*Incheon, Republic of Korea*) 263

Proteome Profiling of Arsenic Trioxide-treated Human Hepatic Cancer Cells. D.R. YOO, S.A. CHONG, M.J. NAM (*Incheon, Republic of Korea*) 269

Chromosomal Alterations in Mini Organ Cultures of Human Oropharyngeal Mucosa Cells Caused by Hydrogen Peroxide. M. REITER, A. SAWICKA, P. BAUMEISTER, C. WELZ, S. SCHWENK-ZIEGER, U. HARRÉUS (*Munich, Germany*)..... 275

Diagnostic MicroRNA Markers for Screening Sporadic Human Colon Cancer and Active Ulcerative Colitis in Stool and Tissue. F.E. AHMED, C.D. JEFFRIES, P.W. VOS, G. FLAKE, G.J. NUOVO, D.R. SINAR, W. NAZIRI, S.P. MARCUARD (*Greenville; Chapel Hill; Research Triangle Park, NC; Columbus, OH, USA*)..... 281

Number 6

Mutations/Polymorphisms in the 55 kDa Subunit of DNA Polymerase ϵ in Human Colorectal Cancer. Q. ZHOU, K. TALVINEN, J. SUNDSTRÖM, A. ELZAGHEID, H. POSPIECH, J.E. SYVÄOJA, Y. COLLAN (*Turku; Oulu; Joensuu, Finland*) 297

* Review: The Continuing Search For Predisposing Colorectal Cancer Variants. S. PICELLI, S. VON HOLST, P. WESSENDORF (*Stockholm, Sweden*) 305

Effects of DNA Threading Bis(9-aminoacridine-4-carboxamides) on Global Gene Expression. M. ZIHLIF, D.R. CATCHPOOLE, B.W. STEWART, L.P.G. WAKELIN (*Amman, Jordan; Westmead; Randwick; Sydney, NSW, Australia*) 317

Interaction of Methylenetetrahydrofolate Reductase Genotype and Smoking Habit in Taiwanese Lung Cancer Patients. C.-S. LIU, C.-W. TSAI, T.-C. HSIA, R.-F. WANG, C.-J. LIU, L.-W. HANG, S.-Y. CHIANG, C.-H. WANG, R.-Y. TSAI, C.-C. LIN, D.-T. BAU (*Taichung, Taiwan, ROC*) 325

A Comparison of Proteomic Profiles Changes during 17 β -Estradiol Treatment in Human Prostate Cancer PC-3 Cell Line. J. CHEN, P. HUANG, H. KAKU, K. ZHANG, M. WATANABE, T. SAIKA, Y. NASU, H. KUMON (*Okayama, Japan; Beijing, P.R. China*) 331

Position Dominant Sequence Elements in Experimentally Verified Human Promoters and their Putative Relation to Cancer. K. VOUGAS, A. SAMARA, G. SPYROU, G.T. TSANGARIS (*Athens, Greece*) 337

Index 2009 357

* Review (page 305)

Subject Index

(Figures refer to page numbers)

- Adenocarcinoma, colonocyte, diagnosis, IBD, LCM, MGB, RT-qPCR, 281
- Affymetrix gene chip microarray, polyamine analogs, PG-11047, colon cancer cells, polyamines, 161
- Antioxidant enzymes, genistein, glutathione S-transferase, NAD(P)H quinone oxidoreductase 1, phase II enzymes, Nrf2, rat, 85
- APC, SNP, linkage disequilibrium, risk, penetrance, polyposis, review, 305
- Apoptosis, resveratrol, 2-dimensional gel electrophoresis, reactive oxygen species, proteomics, SK-HEP-1, hepatic cancer cells, 263
- Arsenic trioxide, proteome profiling, hepatic cancer cells, 269
- Biomarker, lung cancer, comparative proteomics, tandem mass spectrometry, phosphoprotein, 229
- Biomarkers, breast cancer, mass spectrometry, serum archives, SELDI-TOF MS, 141
- Biomarkers, celecoxib, familial adenomatous polyposis, proteomics, 41
- Biomarkers, SELDI-TOF-MS, breast cancer, proteomics, tear fluid, 177
- Biomarkers, SELDI-TOF-MS, breast cancer, proteomics, tear fluid, serum, 75
- Bisintercalating agents, gene expression, DNA binding, 317
- BMPR-IB, bone morphogenetic protein, prognosis, cell proliferation and breast cancer, 101
- Bone morphogenetic protein, BMPR-IB, prognosis, cell proliferation and breast cancer, 101
- BPDE, genotoxicity, xenobiotics, comet FISH, FISH, chromosomal alteration, DNA damage, 247
- BRCA1*, hereditary, breast cancer, mutation, haplotype, 215
- Breast cancer, biomarkers, mass spectrometry, serum archives, SELDI-TOF MS, 141
- Breast cancer, clinical proteomics, microfilament network, disease-specific molecular patterns, predictive diagnosis, 31
- Breast cancer, hereditary, *BRCA1*, mutation, haplotype, 215
- Breast cancer, Kai-1, CD82, invasion, cell migration, 205
- Breast cancer, SELDI-TOF-MS, biomarkers, proteomics, tear fluid, 177
- Breast cancer, SELDI-TOF-MS, biomarkers, proteomics, tear fluid, serum, 75
- Cancer stem cells, phenotypes, metastatic colon cancer, HCT116, microarray, DAVID, 19
- Carcinogenesis, *MTHFR*, polymorphism, lung cancer, 325
- Carcinogens, chemoprevention, chlorophyllin, gene expression, polycyclic aromatic hydrocarbons, 1
- CD82, Kai-1, breast cancer, invasion, cell migration, 205
- Celecoxib, biomarkers, familial adenomatous polyposis, proteomics, 41
- Celecoxib, COX-2 inhibition, gene expression, neo-adjuvant, prostate cancer, 93
- Cell migration, Kai-1, CD82, breast cancer, invasion, 205
- Cell proliferation and breast cancer, bone morphogenetic protein, BMPR-IB, prognosis, 101
- Chemoprevention, carcinogens, chlorophyllin, gene expression, polycyclic aromatic hydrocarbons, 1
- Chemotherapy, microRNA, colorectal cancer, prognosis, review, 195
- Chlorophyllin, carcinogens, chemoprevention, gene expression, polycyclic aromatic hydrocarbons, 1
- Chromosomal alteration, genotoxicity, xenobiotics, BPDE, comet FISH, FISH, DNA damage, 247
- Clinical proteomics, breast cancer, microfilament network, disease-specific molecular patterns, predictive diagnosis, 31
- Colon cancer cells, polyamine analogs, PG-11047, Affymetrix gene chip microarray, polyamines, 161
- Colonocyte, adenocarcinoma, diagnosis, IBD, LCM, MGB, RT-qPCR, 281
- Colorectal cancer, DNA polymerase epsilon (ϵ), genomic changes, 297
- Colorectal cancer, immunohistochemistry, placenta growth factor, prognosis, real-time quantitative polymerase chain reaction, vascular endothelial growth factor, 239
- Colorectal cancer, microRNA, prognosis, chemotherapy, review, 195
- Colorectal cancer, *MTHFR*, polymorphism, Mexican population, 183
- Comet FISH, genotoxicity, hydrogen peroxide, DNA repair, mutagen sensitivity, HNSCC, 275
- Comet FISH, genotoxicity, xenobiotics, BPDE, FISH, chromosomal alteration, DNA damage, 247
- Comparative proteomics, lung cancer, biomarker, tandem mass spectrometry, phosphoprotein, 229
- COX-2 inhibition, celecoxib, gene expression, neo-adjuvant, prostate cancer, 93
- CYP1B1, mRNA, gene expression, 13
- DAVID, cancer stem cells, phenotypes, metastatic colon cancer, HCT116, microarray, 19
- Diagnosis, adenocarcinoma, colonocyte, IBD, LCM, MGB, RT-qPCR, 281
- 2-Dimensional gel electrophoresis, resveratrol, reactive oxygen species, apoptosis, proteomics, SK-HEP-1, hepatic cancer cells, 263
- Disease-specific molecular patterns, breast cancer, clinical proteomics, microfilament network, predictive diagnosis, 31
- DNA binding, gene expression, bisintercalating agents, 317
- DNA damage, genotoxicity, xenobiotics, BPDE, comet FISH, FISH, chromosomal alteration, 247
- DNA polymerase epsilon (ϵ), colorectal cancer, genomic changes, 297
- DNA repair, genotoxicity, hydrogen peroxide, comet FISH, mutagen sensitivity, HNSCC, 275
- ERK, GBM, MAPK, mTOR, RAPA, 255
- Estradiol, ovarian cancer, gene expression, estrogen receptor, genistein, 189
- Estrogen receptor, ovarian cancer, gene expression, genistein, estradiol, 189

- Estrogen, prostate cancer, hTERT, proteomic, 331
- Familial adenomatous polyposis, celecoxib, biomarkers, proteomics, 41
- FISH, genotoxicity, xenobiotics, BPDE, comet FISH, chromosomal alteration, DNA damage, 247
- GBM, ERK, MAPK, mTOR, RAPA, 255
- Gene expression, carcinogens, chemoprevention, chlorophyllin, polycyclic aromatic hydrocarbons, 1
- Gene expression, celecoxib, COX-2 inhibition, neo-adjuvant, prostate cancer, 93
- Gene expression, CYP1B1, mRNA, 13
- Gene expression, DNA binding, bisintercalating agents, 317
- Gene expression, ovarian cancer, estrogen receptor, genistein, estradiol, 189
- Genistein, glutathione S-transferase, NAD(P)H quinone oxidoreductase 1, antioxidant enzymes, phase II enzymes, Nrf2, rat, 85
- Genistein, ovarian cancer, gene expression, estrogen receptor, estradiol, 189
- Genomic changes, colorectal cancer, DNA polymerase epsilon (ϵ), 297
- Genotoxicity, hydrogen peroxide, DNA repair, comet FISH, mutagen sensitivity, HNSCC, 275
- Genotoxicity, xenobiotics, BPDE, comet FISH, FISH, chromosomal alteration, DNA damage, 247
- Glioma, MGMT, temozolomide, survival, 219
- Glutathione S-transferase, genistein, NAD(P)H quinone oxidoreductase 1, antioxidant enzymes, phase II enzymes, Nrf2, rat, 85
- Haplotype, hereditary, breast cancer, *BRCA1*, mutation, 215
- HCT116, cancer stem cells, phenotypes, metastatic colon cancer, microarray, DAVID, 19
- Hepatic cancer cells, arsenic trioxide, proteome profiling, 269
- Hepatic cancer cells, resveratrol, 2-dimensional gel electrophoresis, reactive oxygen species, apoptosis, proteomics, SK-HEP-1, 263
- Hereditary, breast cancer, *BRCA1*, mutation, haplotype, 215
- HNSCC, genotoxicity, hydrogen peroxide, DNA repair, comet FISH, mutagen sensitivity, 275
- hTERT, prostate cancer, estrogen, proteomic, 331
- Human promoters, sequence analysis, positional motifs, 337
- Hydrogen peroxide, genotoxicity, DNA repair, comet FISH, mutagen sensitivity, HNSCC, 275
- IBD, adenocarcinoma, colonocyte, diagnosis, LCM, MGB, RT-qPCR, 281
- Immunohistochemistry, colorectal cancer, placenta growth factor, prognosis, real-time quantitative polymerase chain reaction, vascular endothelial growth factor, 239
- Immuno-histochemistry, proteomics, tumour marker, Western blot, 149
- Invasion, Kai-1, CD82, breast cancer, cell migration, 205
- Invasion, OTSCC, microRNA, miR-222, SOD2, MMP1, 131
- Kai-1, CD82, breast cancer, invasion, cell migration, 205
- LCM, adenocarcinoma, colonocyte, diagnosis, IBD, MGB, RT-qPCR, 281
- Linkage disequilibrium, SNP, APC, risk, penetrance, polyposis, review, 305
- Lung cancer, biomarker, comparative proteomics, tandem mass spectrometry, phosphoprotein, 229
- Lung cancer, *MTHFR*, polymorphism, carcinogenesis, 325
- MAPK, ERK, GBM, mTOR, RAPA, 255
- Mass spectrometry, breast cancer, biomarkers, serum archives, SELDI-TOF MS, 141
- Metastatic colon cancer, cancer stem cells, phenotypes, HCT116, microarray, DAVID, 19
- Mexican population, *MTHFR*, polymorphism, colorectal cancer, 183
- MGB, adenocarcinoma, colonocyte, diagnosis, IBD, LCM, RT-qPCR, 281
- MGMT, glioma, temozolomide, survival, 219
- Microarray, cancer stem cells, phenotypes, metastatic colon cancer, HCT116, DAVID, 19
- Microfilament network, breast cancer, clinical proteomics, disease-specific molecular patterns, predictive diagnosis, 31
- MicroRNA, colorectal cancer, prognosis, chemotherapy, review, 195
- MicroRNA, OTSCC, miR-222, SOD2, MMP1, invasion, 131
- MiR-222, OTSCC, microRNA, SOD2, MMP1, invasion, 131
- Mismatch repair, primers, probes, proteins, QC, RT-qPCR, statistics, Western blots, 109
- MMP1, OTSCC, microRNA, miR-222, SOD2, invasion, 131
- MRNA, CYP1B1, gene expression, 13
- MTHFR*, polymorphism, colorectal cancer, Mexican population, 183
- MTHFR*, polymorphism, lung cancer, carcinogenesis, 325
- MTOR, ERK, GBM, MAPK, RAPA, 255
- Mutagen sensitivity, genotoxicity, hydrogen peroxide, DNA repair, comet FISH, HNSCC, 275
- Mutation, hereditary, breast cancer, *BRCA1*, haplotype, 215
- NAD(P)H quinone oxidoreductase 1, genistein, glutathione S-transferase, antioxidant enzymes, phase II enzymes, Nrf2, rat, 85
- Neo-adjuvant, celecoxib, COX-2 inhibition, gene expression, prostate cancer, 93
- Nrf2, genistein, glutathione S-transferase, NAD(P)H quinone oxidoreductase 1, antioxidant enzymes, phase II enzymes, rat, 85
- OTSCC, microRNA, miR-222, SOD2, MMP1, invasion, 131
- Ovarian cancer, gene expression, estrogen receptor, genistein, estradiol, 189
- Penetrance, SNP, APC, linkage disequilibrium, risk, polyposis, review, 305
- PG-11047, polyamine analogs, colon cancer cells, Affymetrix gene chip microarray, polyamines, 161
- Phase II enzymes, genistein, glutathione S-transferase, NAD(P)H quinone oxidoreductase 1, antioxidant enzymes, Nrf2, rat, 85
- Phenotypes, cancer stem cells, metastatic colon cancer, HCT116, microarray, DAVID, 19
- Phosphoprotein, lung cancer, biomarker, comparative proteomics, tandem mass spectrometry, 229
- Placenta growth factor, colorectal cancer, immunohistochemistry, prognosis, real-time quantitative polymerase chain reaction, vascular endothelial growth factor, 239

- Polyamine analogs, PG-11047, colon cancer cells, Affymetrix gene chip microarray, polyamines, 161
- Polyamines, polyamine analogs, PG-11047, colon cancer cells, Affymetrix gene chip microarray, 161
- Polycyclic aromatic hydrocarbons, carcinogens, chemoprevention, chlorophyllin, gene expression, 1
- Polymorphism, *MTHFR*, colorectal cancer, Mexican population, 183
- Polymorphism, *MTHFR*, lung cancer, carcinogenesis, 325
- Polyposis, SNP, APC, linkage disequilibrium, risk, penetrance, review, 305
- Positional motifs, human promoters, sequence analysis, 337
- Predictive diagnosis, breast cancer, clinical proteomics, microfilament network, disease-specific molecular patterns, 31
- Primers, mismatch repair, probes, proteins, QC, RT-qPCR, statistics, Western blots, 109
- Probes, mismatch repair, primers, proteins, QC, RT-qPCR, statistics, Western blots, 109
- Prognosis, bone morphogenetic protein, BMPR-IB, cell proliferation and breast cancer, 101
- Prognosis, colorectal cancer, immunohistochemistry, placenta growth factor, real-time quantitative polymerase chain reaction, vascular endothelial growth factor, 239
- Prognosis, microRNA, colorectal cancer, chemotherapy, review, 195
- Prostate cancer, celecoxib, COX-2 inhibition, gene expression, neo-adjuvant, 93
- Prostate cancer, estrogen, hTERT, proteomic, 331
- Proteins, mismatch repair, primers, probes, QC, RT-qPCR, statistics, Western blots, 109
- Proteome profiling, arsenic trioxide, hepatic cancer cells, 269
- Proteomic, prostate cancer, estrogen, hTERT, 331
- Proteomics, celecoxib, biomarkers, familial adenomatous polyposis, 41
- Proteomics, resveratrol, 2-dimensional gel electrophoresis, reactive oxygen species, apoptosis, SK-HEP-1, hepatic cancer cells, 263
- Proteomics, SELDI-TOF-MS, breast cancer, biomarkers, tear fluid, 177
- Proteomics, SELDI-TOF-MS, breast cancer, biomarkers, tear fluid, serum, 75
- Proteomics, tumour marker, Western blot, immunohistochemistry, 149
- QC, mismatch repair, primers, probes, proteins, RT-qPCR, statistics, Western blots, 109
- RAPA, ERK, GBM, MAPK, mTOR, 255
- Rat, genistein, glutathione S-transferase, NAD(P)H quinone oxidoreductase 1, antioxidant enzymes, phase II enzymes, Nrf2, 85
- Reactive oxygen species, resveratrol, 2-dimensional gel electrophoresis, apoptosis, proteomics, SK-HEP-1, hepatic cancer cells, 263
- Real-time quantitative polymerase chain reaction, colorectal cancer, immunohistochemistry, placenta growth factor, prognosis, vascular endothelial growth factor, 239
- Resveratrol, 2-dimensional gel electrophoresis, reactive oxygen species, apoptosis, proteomics, SK-HEP-1, hepatic cancer cells, 263
- Review, SNP, APC, linkage disequilibrium, risk, penetrance, polyposis, 305
- Risk, SNP, APC, linkage disequilibrium, penetrance, polyposis, review, 305
- RT-qPCR, adenocarcinoma, colonocyte, diagnosis, IBD, LCM, MGB, 281
- RT-qPCR, mismatch repair, primers, probes, proteins, QC, statistics, Western blots, 109
- SELDI-TOF MS, breast cancer, biomarkers, mass spectrometry, serum archives, 141
- SELDI-TOF-MS, breast cancer, biomarkers, proteomics, tear fluid, 177
- SELDI-TOF-MS, breast cancer, biomarkers, proteomics, tear fluid, serum, 75
- Sequence analysis, human promoters, positional motifs, 337
- Serum archives, breast cancer, biomarkers, mass spectrometry, SELDI-TOF MS, 141
- Serum, SELDI-TOF-MS, breast cancer, biomarkers, proteomics, tear fluid, 75
- SK-HEP-1, resveratrol, 2-dimensional gel electrophoresis, reactive oxygen species, apoptosis, proteomics, hepatic cancer cells, 263
- SNP, APC, linkage disequilibrium, risk, penetrance, polyposis, review, 305
- SOD2, OTSCC, microRNA, miR-222, MMP1, invasion, 131
- Statistics, mismatch repair, primers, probes, proteins, QC, RT-qPCR, Western blots, 109
- Survival, glioma, MGMT, temozolomide, 219
- Tandem mass spectrometry, lung cancer, biomarker, comparative proteomics, phosphoprotein, 229
- Tear fluid, SELDI-TOF-MS, breast cancer, biomarkers, proteomics, 177
- Tear fluid, SELDI-TOF-MS, breast cancer, biomarkers, proteomics, serum, 75
- Temozolomide, glioma, MGMT, survival, 219
- Tumour marker, proteomics, Western blot, immunohistochemistry, 149
- Vascular endothelial growth factor, colorectal cancer, immunohistochemistry, placenta growth factor, prognosis, real-time quantitative polymerase chain reaction, 239
- Western blot, proteomics, tumour marker, immunohistochemistry, 149
- Western blots, mismatch repair, primers, probes, proteins, QC, RT-qPCR, statistics, 109
- Xenobiotics, genotoxicity, BPDE, comet FISH, FISH, chromosomal alteration, DNA damage, 247

Authors Index

(Figures refer to page numbers)

- Ahmed FE, 109, 281
 Albert L, 255
 Ali IU, 41
 Allison RR, 109
 Annovazzi L, 219
 Antti H, 149
 Apressos A, 215
 Bau D-T, 325
 Baumeister P, 247, 275
 Belogianni I, 215
 Bergh A, 149
 Boehm D, 75, 177
 Boesch-Saadatmandi C, 85
 Bokobza SM, 101
 Bonnerup C, 109
 Boring D, 41
 Botchkina GI, 19
 Botchkina IL, 19
 Braun M, 31
 Bucca G, 93
 Caldera V, 219
 Cassoni P, 219
 Catchpoole DR, 317
 Chelius D, 41
 Chen J, 331
 Chiablaem K, 229
 Chiang S-Y, 325
 Chiò A, 219
 Choi HY, 263
 Chokchaichamnankit D, 229
 Chong SA, 263, 269
 Coley HM, 93
 Collan Y, 297
 Coulton GR, 141
 Crawford H, 19
 Croce CM, 195
 Cutress RI, 141
 Davies ML, 239
 Döhrel J, 13
 Dufour A, 19
 Elzagheid A, 297
 Escudero-Esparza A, 239
 Fabbri M, 195
 Fatima N, 41
 Figuera LE, 183
 Finocchiaro G, 219
 Flake G, 281
 Fountoulakis M, 31
 Gallegos-Arreola MP, 183
 Gareva-Ortiz JE, 183
 Gercel-Taylor C, 189
 Gerner EW, 161
 Golubnitschaja O, 31
 Greenwald P, 41
 Grus FH, 75, 177
 Guszczynski T, 41
 Hadzaad B, 13
 Hang L-W, 325
 Harréus U, 247, 275
 Hastie C, 141
 Helmig S, 13
 Henderson A, 93
 Höller T, 31
 Hsia T-C, 325
 Huang P, 331
 Ignatenko NA, 161
 Jeffries CD, 109, 281
 Jhanwar-Uniyal M, 255
 Jiang L, 131
 Jiang WG, 101, 205, 239
 Ju J, 19
 Kachel KL, 161
 Kaku H, 331
 Karphe MS Jr, 19
 Karsy M, 255
 Kayani MA, 205
 Keshava C, 1
 Kesterson S, 189
 Koelbl H, 75, 177
 Kruse H-P, 85
 Kuhn W, 31
 Kulling S, 85
 Kumon H, 331
 Kynaston HE, 101
 Kyriakopoulou V, 215
 Labropoulos S, 215
 Laing EE, 93
 Laing RW, 93
 Langley SEM, 93
 Lanotte M, 219
 Lebrecht A, 75, 177
 Leyfman Y, 19
 Lin C-C, 325
 Lindahl C, 149
 Liu C-J, 325
 Liu C-S, 325
 Liu X, 131
 Luke BT, 41
 Lynch P, 41
 Macanas-Pirard P, 93
 Malik FA, 205
 Mansel RE, 101
 Marcuard SP, 281
 Martin TA, 239
 Marton LJ, 161
 Mellai M, 219
 Miller K, 41
 Morganville G, 183
 Mota H, 109
 Murali R, 255
 Murray N, 141
 Nam MJ, 263, 269
 Nasioulas G, 215
 Nasu Y, 331
 Nath J, 1
 Naziri, W, 281
 Nuovo GJ, 281
 Packham G, 141
 Pandey R, 161
 Papadopoulou A, 31
 Papadopoulou E, 215
 Parker LP, 189
 Picelli S, 305
 Pospiech H, 297
 Puebla-Pérez AM, 183
 Razis E, 215
 Reiter M, 247, 275
 Richardson DL, 1
 Rimbach G, 85
 Rivadeneira DE, 19
 Rowehl RA, 19
 Rubporn A, 229
 Saika T, 331
 Samara A, 337
 Sanders AJ, 205
 Sangvanich P, 229
 Sariyanni M, 215
 Sawicka A, 275
 Schiffer D, 219
 Schild HH, 31
 Schmidt M, 75, 177
 Schneider J, 13
 Schwenk-Zieger S, 275
 Schwirz RL, 177
 Seidel I, 31
 Shi F, 131
 Siamanta V, 215
 Sibata C, 109
 Simonsson M, 149
 Sinar DR, 281
 Smith CP, 93
 Sooriakumaran P, 93
 Spyrou G, 337
 Srisomsap C, 229
 Stauffer S, 41
 Stephens R, 41
 Stewart BW, 317
 Stringer DE, 161
 Subhasitanont P, 229
 Sund M, 149
 Sundström J, 297
 Svasti J, 229
 Syväoja JE, 297
 Talvinen K, 297
 Taylor DD, 189
 Theofilopoulos D, 215
 Thysell E, 149
 Townsend PA, 141
 Tsai C-W, 325
 Tsai R-Y, 325
 Tsangaris GT, 337
 Valeri N, 195
 Von Holst S, 305
 Vos PW, 109, 281
 Vougas K, 31, 337
 Wagner AE, 85
 Wakelin LPG, 317
 Wang A, 131
 Wang C-H, 325
 Wang R-F, 325
 Wang Y, 19
 Watanabe M, 331
 Weidner DA, 109
 Welz C, 275
 Wessendorf P, 305
 Weston A, 1
 Wiegand H, 85
 Wikström P, 149
 Wiley JE, 109
 Ye H, 131
 Ye L, 101
 Yeghiazaryan K, 31
 Yerushalmi HF, 161
 Yi M, 41
 Yoo DR, 269
 Yu J, 131
 Zeidan BA, 141
 Zhang K, 331
 Zhang T, 41
 Zhou Q, 297
 Zhou X, 131
 Zieger S, 247
 Zihlif M, 317
 Zúñiga-González GM, 183

Errata

Volume 5, Number 6, page 321, right column, last line, please change to:
exhibited a fold change of -4.0 in response to the OTA treatment.

Volume 5, Number 6, page 322, Table II, 4th column, 8th line:
Please correct “Mitochndrial” to “Mitochondrial”

Volume 5, Number 6, page 322, Table II, 4th column, 25th line:
Please correct “improtant” to “important”

Volume 5, Number 6, page 322, Table III, 3rd column, 10th line, please add:
B4GALT7

Volume 5, Number 6, page 324, Table Vb, 2nd column, 2nd line:
Please correct “famly” to “family” .

Volume 5, Number 6, page 324, Table Vb, 2nd column, 12th line:
Please correct “acetylglucosaminephospho-transferase 1” to “acetylglucosaminephospho-transferase 1” .

Volume 5, Number 6, page 325, Table VI, 4th column, 14th line:
Please correct “cenrosomes” to “centrosomes” .

Volume 6, Number 1, page 15, the legend of Figure 3 should read:

Figure 3. Melting curve analyses for Cyp1B1 gene expression. Fluorescence data were converted to derivative melting curves by plotting the negative derivate of the fluorescence with respect to temperature vs. temperature $[-(dF/dT)$ vs. T] and show one PCR product peak at 89°C visible for the target PCR. The negative control shows no visible PCR product.

CANCER GENOMICS & PROTEOMICS supports (a) the aims and the research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR, Kapandriti, Attiki, Greece) and (b) the organization of the International Conferences of Anticancer Research.

For more information about CANCER GENOMICS & PROTEOMICS, IIAR and the Conferences please visit our websites: www.iiar-anticancer.org, www.cgp.iiarjournals.org

Publication Data: CANCER GENOMICS & PROTEOMICS (CGP) is published bimonthly. Each annual volume contains six issues. Annual Authors and Subject Indexes are included in the sixth issue of each volume.

Copyright: Once a manuscript has been published in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author to the Journal.

Manuscripts, correspondence, requests for sample copies and orders should be addressed to: Dr. John G. Delinassios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: journals@iiar-anticancer.org (Editorial Office), editor@iiar-anticancer.org (Managing Editor).

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5. Fax: 416 978 5956, e-mail: genomics.proteomics@utoronto.ca

Annual Subscription (print and online) Rates 2010: Institutional subscription: Euro 800 per volume. Personal subscription: Euro 400 per volume. Prices include rapid delivery and insurance. Previous volumes (2004-2009) are available at 50% discount.

Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the publisher. Cheques should be made payable to J.G. Delinassios, Managing Editor, Athens, Greece, and should be sent to the Editorial Office.

Advertising: Correspondence and rate requests should be addressed to the Editorial Office.

Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

The Editors and Publishers of the journal CANCER GENOMICS & PROTEOMICS accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing therein.